Yongdong Jin

机构：Sichuan Cancer Hospital

发表论文 18 篇 · 总被引 117 次 · h-index 6

代表论文

• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 45)
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 24)
• Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers (2024 · Cancer Immunology Immunotherapy · 被引 16)
• Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis (2022 · Frontiers in Immunology · 被引 10)
• Laser heterodyne vibration measuring method (1988 · Optics & Laser Technology · 被引 8)
• Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition) (2024 · Liver Cancer · 被引 7)